San Francisco / USA, to evaluate the safety of PRT4445, an investigational antidote for Factor Xa inhibitors, in healthy volunteers who have been administered the oral anticoagulant XareltoA (rivaroxaban).
What does FXa stand for?
FXa stands for Factor Xa (biochemistry)
This definition appears very frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of FXa
We have 1 other meaning of FXa in our Acronym Attic
- Fragilex Syndrome (genetic disorder causing mental retardation)
- Fuji Xerox (various locations)
- Full Duplex
- Functional Exercise (various organizations)
- Foreign Exchange Joint Standing Committee (Bank of England; also seen as FXJSC)
- Foreign Exchange Trunk Operation
- FSL X Window AWIPS-Like Prototype for Hydrometeorological Applications
- Feature Extractor/Processor
- Second Generation Effects (film company)
- Foreign Exchange Agreement
- Foreign Exchange Analytics (Asian and European market analysis)
- Fuji Xerox Australia
- Factor X-Activating Activity
- Fast Approximate Anti-Aliasing (algorithm)
- Factor X Activation Peptide
- Fuji Xerox Asia Pacific
- Fuji Xerox Advanced Technology Co., Ltd. (Japan)
- Fragile X Association of Washington State (disability support group)
- Festival of Xtreme Building (Birmingham, England, UK)
Samples in periodicals archive:
and Bayer HealthCare to evaluate the safety of PRT4445 - an investigational-stage antidote for Factor Xa inhibitors - in healthy volunteers who have been administered the oral anticoagulant XARELTO[sup.
TOKYO, October 25, 2012 /PRNewswire/ -- Edoxaban is an investigational, once daily, novel oral factor Xa inhibitor Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has completed patient enrolment in the global Hokusai-VTE phase 3 study investigating the once-daily oral factor Xa inhibitor edoxaban for the treatment and prevention of recurrence of venous thromboembolism (VTE) in patients who have had an acute symptomatic deep vein thrombosis (DVT), pulmonary embolism (PE), or both.
The comparison of factor Xa inhibitors fondaparinux and idraparinux with warfarin resulted in fewer emboli but more bleeding.
Moreover, she has seen thromboembolic complications occur even when LMWH dosing was guided by monitoring of factor Xa levels rather than relying on fixed-dose therapy.
The new compounds inhibit a clot-promoting blood molecule called factor Xa.
Fondapariux sodium is a selective inhibitor of Factor Xa, a protein central to the coagulation process.
Since enoxaparin is highly active against factor Xa, anti-factor Xa values that are within the determined therapeutic range are consistent with adequate drug efficacy and safety.